GlassScriptPhysician profile
Sudarshan Rajagopal
NPI 1134391253
$139,038.11
in general payments reported to CMS, 2019-2025
11 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $9,470 · 2021: $7,394 · 2022: $17K · 2023: $21K · 2024: $20K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $75K · Travel and Lodging: $9,755 · Food and Beverage: $3,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,163.28 |
| Travel and Lodging | $9,755.25 |
| Food and Beverage | $3,788.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $62,911.28 | 2019-2025 | Tyvaso, Remodulin, Remodulin |
| Merck Sharp & Dohme LLC | $49,617.63 | 2022-2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $20,119.75 | 2019-2024 | Uptravi, Opsumit |
| Insmed, INC. | $4,241.25 | 2020-2022 | |
| Otsuka Pharmaceutical Co., LTD. | $2,068.28 | 2023 | |
| Stryker Corporation | $42.76 | 2025 | Flowtriever |
| Janssen Research & Development, LLC | $37.16 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudarshan Rajagopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.